Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

References

• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network streptococcus pneumoniate, provisional-2009 [web-based report]. [accessed 2018 Mar 29] http://www.cdc.gov/abc.
   Google Scholar
• Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, et al.. Epidemiology of invasive streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report emerging infections program network streptococcus pneumoniae, 1997 [web-based report]. [accessed 2018 Mar 29]. http://www.cdc.gov/ncidod/dbmd/abcs.
   Google Scholar
• Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398–3412. doi:10.1016/j.vaccine.2011.02.088.
   PubMed Web of Science ®Google Scholar
• Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis. 2004;4:112–124. doi:10.1016/S1473-3099(04)00931-4.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386. doi:10.1086/431521.
   PubMed Web of Science ®Google Scholar
• Cané A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015;37:30–35. doi:10.1016/j.ijid.2015.05.003.
   PubMed Web of Science ®Google Scholar
• Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B, Klein NP. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016;34:4293–4297. doi:10.1016/j.vaccine.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Morton JB, Morrill HJ, LaPlante KL, Caffrey AR. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections. Vaccine. 2017;35:1692–1697. doi:10.1016/j.vaccine.2017.02.026.
   PubMed Web of Science ®Google Scholar
• Prevnar [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals Inc. [accessed 2018 Mar 29]. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm137038.pdf.
   Google Scholar
• Synflorix [package insert]. Rixensart (Belgium): GlaxoSmithKline Biologicals s.a. [accessed 2018 Mar 29]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf.
   Google Scholar
• Prevnar 13 [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals Inc. [accessed 2018 Mar 29]. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM574852.pdf.
   Google Scholar
• Kaplan SL, Center KJ, Barson WJ, Ling-Lin P, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Peters TR, Gurtman A, et al.. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60:1339–1345. doi:10.1093/cid/civ067.
   PubMed Web of Science ®Google Scholar
• Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58:6484–6489. doi:10.1128/AAC.03344-14.
   PubMed Web of Science ®Google Scholar
• Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, Sherwood L, Zmitrovich A, Jerris R, Satola SW, et al.. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34:1168–1174. doi:10.1097/INF.0000000000000849.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, et al.. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58:918–924. doi:10.1093/cid/ciu006.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–163. doi:10.1056/NEJMoa1209165.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2:387–394. doi:10.1016/S2213-2600(14)70032-3.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45:1632–1641. doi:10.1183/09031936.00183614.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010;29:283–288. doi:10.1016/j.vaccine.2010.10.032.
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, et al.. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013;59:778–788. doi:10.1139/cjm-2013-0614.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al.. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543. doi:10.1016/S1473-3099(15)70044-7.
   PubMed Web of Science ®Google Scholar
• Sobanjo-Ter Meulen A, Vesikari T, Malacaman EA, Shapiro SA, Dallas MJ, Hoover PA, McFetridge R, Stek JE, Marchese RD, Hartzel J, et al.. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:186–194. doi:10.1097/INF.0000000000000516.
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis. 2009;49:241–248. doi:10.1086/599824.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31:3594–3602. doi:10.1016/j.vaccine.2013.04.084.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine. 2014;32:2364–2374. doi:10.1016/j.vaccine.2014.02.002.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir ST, Center KJ, Davidsdottir K, Arason VA, Hjalmarsson B, Elisdottir R, Ingolfsdottir G, Northington R, Scott DA, Jonsdottir I. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Vaccine. 2014;32:417–424. doi:10.1016/j.vaccine.2013.11.029.
   PubMed Web of Science ®Google Scholar
• Moberley S, Licciardi PV, Balloch A, Andrews R, Leach AJ, Kirkwood M, Binks P, Mulholland K, Carapetis J, Tang MLK, et al. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness. Vaccine. 2017;35:2908–2915. doi:10.1016/j.vaccine.2017.04.040.
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, Tikoduadua L, Waqatakirewa L, Pryor J, Nelson J, Byrnes GB, et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 2010;28:3341–3349. doi:10.1016/j.vaccine.2010.02.087.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–3593. doi:10.1016/j.vaccine.2013.05.010.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Mmwr. 2015;64:944–947. doi:10.15585/mmwr.mm6434a4.
   PubMed Web of Science ®Google Scholar
• Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018;36(45):6875–6882.  doi:10.1016/j.vaccine.2018.03.012.
   PubMedGoogle Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413. doi:10.1093/biomet/26.4.404.
   Web of Science ®Google Scholar
• Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankyha: Indian J Stat. 2000;62(Series B, Part 1):134–148.
   Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226.
   PubMed Web of Science ®Google Scholar